Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $670,258.26 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 7,287 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the sale, the chief financial officer directly owned 49,788 shares of the company’s stock, valued at $4,579,500.24. This represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, January 26th, Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total value of $101,288.07.
• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $132,621.93.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $90.72 on Friday. The company has a market cap of $5.47 billion, a P/E ratio of -189.00 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $109.28. The business has a fifty day moving average of $96.51 and a two-hundred day moving average of $81.14. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MIRM shares. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Morgan Stanley boosted their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Royal Bank Of Canada reduced their price objective on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Finally, Stifel Nicolaus boosted their target price on Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIRM. Janus Henderson Group PLC grew its holdings in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after buying an additional 1,067,722 shares during the last quarter. State Street Corp lifted its position in shares of Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after acquiring an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after acquiring an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after acquiring an additional 371,999 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.